The Latest Cardiac and Vascular News
PARIS–(BUSINESS WIRE)–Regulatory News: “I’m very pleased with the progress of the EFICAS study, both in terms of the pace of inclusion and results observed to date. ” Post this CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for […]
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) were […]
COLLEGEVILLE, Pa.–(BUSINESS WIRE)–Thubrikar Aortic Valve, Inc. today announced successful results in the first two patients implanted with the Optimum Transcatheter Aortic Valve (Optimum TAV™) using the new Precision 2™ Delivery Catheter. Interventional Cardiologist and TAVI-1 Study Principal Investigator, Jaroslaw Trebacz, MD, performed the procedures at the John Paul II Hospital […]
SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024.
MENLO PARK, Calif., May 6, 2024 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”), a pioneering medical device company at the forefront of advancing clot removal technologies for venous thromboembolism (VTE), proudly announced positive safety and feasibility results from its ENGULF US…
Funding supports commercial expansion of inHEART’s digital twin of the heart in the US, EU, Asia Pacific, and Middle East markets, as well as the development of new software solutions across the cardiac care continuum CAMBRIDGE, Mass. and BORDEAUX, France, May 6, 2024 /PRNewswire/ –…
IRVINE, Calif., May 06, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the upcoming Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024, at 11:20 AM Pacific Time.
WEST VALLEY CITY, Utah, May 6, 2024 /PRNewswire/ — Scientia Vascular, a leader in neurovascular innovation, is thrilled to announce the FDA clearance of two uniquely engineered catheters: the Plato 17—a DMSO-compatible microcatheter—and the Socrates 38, an aspiration catheter engineered…
Experts in Vascular Surgery, Interventional Radiology and Interventional Cardiology to Help Guide Commercialization SAN DIEGO, May 6, 2024 /PRNewswire/ — Provisio Medical, Inc. today announced the formation of a Physician Advisory Board (PAB) comprising a multidisciplinary group of…
NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 30,000 of NewAmsterdam’s ordinary shares to three non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
